Idarubicine
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
The First Affiliated Hospital of Soochow UniversityPhase 2Active
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 64/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Alice Mims | Phase 3 | BBB |
Daunorubicin National Cancer Institute (NCI) | Phase 3 | BBB |
Cytosin-Arabinosid The First Affiliated Hospital of Soochow University | Phase 3 | BBB |
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- National Cancer Institute (NCI) | Phase 2 | BBB |
Cyclophosphamide BGI, China | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Idarubicine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →